Finvest
QURE Biotechnology · Gene therapy · Clinical stage · Rare disease · Thesis updated July 2, 2026

A U.K. opening, but U.S. doubt still rules

01 Running thesis

One asset, two regulators

uniQure is now a split story. In the U.K., AMT-130 may move toward a filing soon. The company said it plans to submit a Marketing Authorization Application in Q3 2026 after feedback from the MHRA, the U.K. medicines regulator.

That matters because the U.S. path has become much harder. The FDA said the existing Phase I/II data, compared with an outside control group, are not enough as the main proof of effectiveness. It strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. In plain English, the FDA wants a new trial where some patients get a fake surgery control, so the study can better test whether AMT-130 truly works.

The bull case is that the U.K. filing creates a real near-term path to market. A U.K. approval could validate AMT-130, help other non-U.S. filings, and give investors proof that regulators can accept the current data package. Cash guidance into the second half of 2029 gives the company time to try.

The bear case is that the U.S. is still the biggest prize, and that road now likely needs a long and costly pivotal trial. The company has not yet given the design, timeline, or estimated cost. That makes the runway less clean than it looks and keeps financing risk alive. The stock also already depends heavily on AMT-130, so one regulatory setback can move the whole story.

May 2026▲uniQure added a major new catalyst by planning a U.K. AMT-130 filing in Q3 2026 after MHRA feedback. It also extended cash runway guidance into the second half of 2029, but the future U.S. trial cost remains an open issue.
May 2026▼The company formally discontinued AMT-162 for ALS. That narrows the pipeline and makes AMT-130 even more important.
Mar 2026▼The FDA's position on AMT-130 became clear. It does not view the Phase I/II data with an external control as enough main proof for a U.S. marketing application and strongly recommended a new sham-controlled study.
Mar 2026→Management planned a Q2 2026 Type B meeting with the FDA to discuss the U.S. pivotal trial design. This gave investors a next step, but not yet a cost or timeline.
Nov 2025▼The earlier plan for a near-term U.S. BLA filing broke after the FDA no longer appeared to support the external control pathway. Positive 3-year data could not remove the regulatory overhang.
Nov 2025▲uniQure reported positive 3-year AMT-130 data and a much larger cash balance after financing. That supported the science case, even as the U.S. regulatory path worsened.
Jul 2025▲The company had previously reported FDA alignment on the AMT-130 statistical analysis plan and CMC path for a planned BLA. That was the old bull case before the later FDA reversal.
02 Business model

Royalties fund a trial story

uniQure develops one-time gene therapies for serious diseases. These treatments try to fix or change disease biology with a single administration, instead of chronic dosing.

The only approved product tied to uniQure is HEMGENIX for Hemophilia B. CSL Behring commercializes it, and uniQure receives license revenue, mainly royalties. In Q1 2026, the company reported license revenue as all of its revenue for the quarter.

The company used to run more of its own manufacturing. It has shifted to an outsourced model after divesting its main manufacturing facility to Genezen. Genezen now matters because uniQure depends on it for HEMGENIX supply work and for clinical materials.

The business breaks if AMT-130 fails to reach approval, if regulators demand trials the company cannot fund, or if outsourced manufacturing cannot meet quality rules. HEMGENIX royalties help, but the company is still a clinical-stage biotech with losses.

03 Product portfolio

What uniQure is betting on

Growth engine

AMT-130

AMT-130 is the lead program for Huntington's disease. The U.K. filing planned for Q3 2026 is the key near-term catalyst, while the U.S. path likely needs a new pivotal trial.

Cash cow

HEMGENIX

HEMGENIX is an approved gene therapy for Hemophilia B, sold by CSL Behring. uniQure gets royalties and possible milestones, but this revenue stream is not the main driver of the stock today.

Option

AMT-260

AMT-260 is in a Phase I/IIa trial for refractory mesial temporal lobe epilepsy. It gives uniQure another clinical shot, but it is earlier than AMT-130.

Option

AMT-191

AMT-191 is in a Phase I/IIa trial for Fabry disease. Dosing in the mid- and high-dose cohorts has been paused after dose-limiting toxicities, so safety is the key issue to watch.

04 Business segments

Revenue is one stream today

License revenues100%growing fast
Contract manufacturing revenues0%declining
Collaboration revenues0%flat

For Q1 2026, uniQure reported total revenue as license revenue. The company says it has one business segment, so the mix below shows reported revenue streams, not separate operating divisions.

05 Risk factors

What could break the story

FDA trial reset

High impact · High odds

The FDA has said the current AMT-130 Phase I/II data with an external control are not enough as the main proof for a U.S. filing. It strongly recommended a new sham surgery-controlled trial. That could add years, raise costs, and delay access to the largest market.

We watchFDA Type B meeting feedback, then the announced U.S. pivotal trial design, timeline, and cost.

U.K. filing disappointment

High impact · Medium odds

The U.K. path is the new upside case, but it is not approval. The MHRA still has to decide whether the Phase I/II data and external control can support a marketing application. A refusal or long review would weaken the main near-term catalyst.

We watchAMT-130 U.K. Marketing Authorization Application submission in Q3 2026 and any MHRA review timeline.

Runway may shrink

High impact · Medium odds

uniQure guides for cash into the second half of 2029. That guidance is helpful, but the cost of the expected U.S. AMT-130 pivotal trial is still not pinned down. If the trial is large or slow, the company may need more capital sooner than investors expect.

We watchManagement's estimate of AMT-130 pivotal trial spending and any equity or debt financing.

Pipeline safety setbacks

Medium impact · Medium odds

The pipeline outside AMT-130 has already shown stress. AMT-162 for ALS was discontinued, and AMT-191 dosing in higher cohorts has been paused after dose-limiting toxicities. That leaves less room for a backup story if AMT-130 stumbles.

We watchAMT-191 safety update and whether dosing in paused cohorts resumes.

Genezen dependence

Medium impact · Low odds

uniQure now relies more on Genezen for manufacturing support after moving away from owning its main facility. Gene therapy manufacturing is complex, and quality issues can slow trials or filings. This is secondary to the FDA issue, but it still matters.

We watchAny CMC, supply, or manufacturing delay tied to AMT-130, AMT-260, AMT-191, or HEMGENIX.
06 Quick answers

In one breath

What is uniQure's most important drug?

AMT-130 is the most important program. It targets Huntington's disease and now has a planned U.K. filing in Q3 2026, while the U.S. path likely needs a new pivotal trial.

Does uniQure already sell a product?

uniQure benefits from HEMGENIX, an approved Hemophilia B gene therapy sold by CSL Behring. uniQure receives royalties and possible milestones rather than running the main commercial effort itself.

Why did the uniQure thesis change in 2026?

The FDA made clear that it does not accept the current AMT-130 data package as the main proof for a U.S. marketing application. Later, uniQure said it plans to file in the U.K., creating a second path that may move faster.